WEP-CLINICAL
5.4.2022 15:10:12 CEST | Business Wire | Press release
WEP Clinical (WEP), a specialist services company that works with sponsors to help patients and physicians gain early access to medicines when no other treatment options are available, has appointed Karl Challender as the company’s Chief Operating Officer. Karl has been brought on to lead the company’s global operations and drive WEP’s growth and development strategy moving forward.
Karl has over 25 years of experience in the pharmaceutical and clinical research industry and brings with him a wealth of functional experience covering areas including Operations, Finance, Logistics, Project Management and Sales. Prior to joining WEP, Karl worked with organisations including Novartis, Alcon, and most recently Worldwide Clinical Trials, where he was instrumental in the successful growth of the organisation.
Jaswinder Khera, Managing Director of WEP, said:
“WEP has grown rapidly over the last few years. We are excited to see this continue and are confident that Karl’s expansive industry experience and expertise will help elevate our position as the global leader in Expanded Access and Named Patient Programs. Karl is an excellent addition to our team and his passion for patient service and delivery excellence is well aligned with our company ethos and goals.”
About WEP
Established in 2008, WEP is a specialist services company that works with drug developers to help patients and physicians gain early access to medicines when no other treatment options are available. We have offices located in London, United Kingdom; RTP North Carolina, United States; Lisbon, Portugal; and Dublin, Ireland and possess all the necessary licenses allowing us to meet drug access and distribution needs across all regions, worldwide. We are passionate about helping those in need. For more information, please visit www.wepclinical.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005667/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CreditNature and Stabiliti Partner to Embed Nature Finance into Everyday Economic Activity19.5.2026 14:48:00 CEST | Press release
CreditNature, a leading international Nature Fintech company, is proud to announce a strategic partnership with Stabiliti, which enables businesses to seamlessly integrate verified nature restoration into core economic activity and financial flows, unlocking scalable investment for ecosystem recovery. CreditNature, a pioneering Nature Fintech company, today announces a strategic partnership with Stabiliti, a nature-focused technology company building the infrastructure to embed environmental contributions into everyday economic activity. Together, the partnership will enable businesses to embed measurable nature impact into everyday operations, bridging the gap between commercial activity and ecosystem restoration at unprecedented scale. The collaboration addresses a critical challenge in nature finance: how to mobilise investment at the scale required to meet global biodiversity targets. By integrating CreditNature's scientifically accredited NARIA framework with Stabiliti's embedded
Gustave Roussy and One Biosciences Partner to Bring Single Cell to Clinical Practice for Precision Oncology19.5.2026 13:02:00 CEST | Press release
Gustave Roussy partners with One Biosciences, a techbio company that harnesses single cell technology and AI to develop advanced precision diagnostics. The collaboration aims to further demonstrate the feasibility and impact of integrating single nuclei transcriptomic analysis into the patient care pathway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519540709/en/ Gustave Roussy, Europe’s leading cancer center, is teaming up with One Biosciences to harness the cutting-edge potential of OneMapTM, the single-cell and AI-powered solution helping to enhance precision oncology solutions. By analyzing anonymized frozen samples across four cancer indications, One Biosciences will deploy OneMapTM to generate ultra-high-resolution single-cell data, unlocking the hidden functional diversity of each tumor with unparalleled precision. Prof. Sophie Postel-Vinay, oncologist at Gustave Roussy, team leader in Inserm unit U981 at Gusta
InterSystems IntelliCare Becomes the First AI-Native EHR to Achieve EU Medical Device Regulation Certification19.5.2026 13:00:00 CEST | Press release
Regulatory milestone reaffirms InterSystems as a leading provider of enterprise-grade AI applications InterSystems, a creative data technology provider powering more than one billion health records globally, today announced that its electronic health record (EHR) solutions have been certified as Class IIa Medical Devices under Regulation (MDR) certification under Regulation (EU) 2017/745. This approval marks the first fully unified AI-native EHR to achieve MDR Class IIa certification in the European Union. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519124986/en/ This certification demonstrates that InterSystems AI-native EHR meets stringent EU safety and quality standards. This key milestone has significant implications for how healthcare organizations can responsibly scale AI while building confidence among healthcare providers and regulators. InterSystems has secured MDR certification for InterSystems IntelliCare™,
Venionaire Capital Mandated to Structure KISAB’s Next Growth Round19.5.2026 12:41:00 CEST | Press release
Growth round to target growth private equity and strategic investors as KISAB advances its 8-inch BPD-free SiC wafer platform Venionaire Capital has been mandated by Kiselkarbid i Stockholm AB (“KISAB”) to structure and support the company’s next growth round. The mandate includes investor relations, investor communications and strategic financing preparation, targeting growth private equity and strategic investors. KISAB is a Sweden-based silicon carbide semiconductor materials company focused on advanced SiC substrates for power electronics. The company publicly highlights its 8-inch BPD-free n-type silicon carbide wafers, with the 8-inch platform representing an important technological step for next-generation high-performance power electronics. KISAB has previously attracted approximately EUR 24 million across several financing rounds. Publicly named investors include Fairpoint Capital, Industrifonden and Ingka GreenTech. Venionaire Capital will now support the company in sharpenin
motif Launches Clarity, a First-of-Its-Kind AI Financial Intelligence System19.5.2026 12:39:00 CEST | Press release
Clarity applies contextual understanding to market intelligence, enabling auditable, high-quality AI wealth advisory for financial institutions motif, the AI wealth advisory company backed by Liminal (a venture creation group founded by Temasek), today launched Clarity, an AI financial intelligence system that tracks how markets, assets and financial relationships connect, and how and why they change over time, building enriched connections that deliver the kind of structured, sourced insight that financial institutions have never had, even with dedicated analyst teams. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511241653/en/ motif Launches Clarity, a First-of-Its-Kind AI Financial Intelligence System Financial institutions integrate Clarity into their products so customers can make better-informed investment decisions, while analysts and product teams use it to track market shifts and plan accordingly. Informed inves
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom